安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察

目的 研究安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效。方法 选取2017年9月~2018年9月十堰市人民医院收治的48例晚期卵巢癌并发腹腔积液患者为研究对象，随机分为实验组和对照组，各24例。对照组静脉给予顺铂治疗，实验组在对照组基础上加用安罗替尼治疗，比较两组患者的临床疗效、不良反应发生情况及生活质量改善情况，并检测腹腔积液CA125水平。结果 实验组患者的近期疗效总有效率高于对照组（87.50% vs 58.33%），差异有统计学意义（P＜0.05）。实验组治疗后1、2、3周腹腔积液CA125水平低于对照组，差异有统计学意义（P＜0.05）。两组不良反应发生率比较，差异无统计学意义（P＞0.05）。观察组患者的生活质量改善率高于对照组（83.33% vs 54.17%），差异有统计学有意义（P＜0.05）。结论 安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效显著，不仅可明显改善患者生活质量、降低其不良反应发生率，而且可降低CA125水平，患者耐受程度较好，值得临床参考。

Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites

Abstract:Objective To study the efficacy of ilotinib combined with cisplatin in the treatment of advanced ovarian cancer with malignant ascites. Methods 48 patients with advanced ovarian cancer complicated with ascites were enrolled in the Shiyan People’s Hospital from September 2017 to September 2018. They were randomly divided into experimental group and control group, 24 cases each. The control group was treated with cisplatin intravenously. The experimental group was treated with ilotinib on the basis of the control group. The clinical efficacy, adverse reaction and quality of life were compared between the two groups, and the level of CA125 in the peritoneal effusion was measured. Results The total effective rate of the short-term efficacy of the experimental group was higher than that of the control group (87.50% vs 58.33%),the difference was statistically significant (P<0.05). The level of CA125 in the ascites of the experimental group was lower than that of the control group at 1, 2, and 3 weeks after treatment,the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The improvement rate of quality of life in the observation group was higher than that in the control group (83.33% vs 54.17%),the difference was statistically significant (P<0.05). Conclusion The efficacy of erlotinib combined with cisplatin in the treatment of advanced ovarian cancer malignant ascites is significant, not only can significantly improve the quality of life of patients, reduce the incidence of adverse reactions, but also reduce the level of CA125, patients with better tolerance, worthy of clinical reference.